VandetanibIn Medullary Thyroid Cancer

被引：0
作者：
James E. Frampton
机构：
[1] Adis,
来源：
Drugs | 2012年 / 72卷
关键词：
Epidermal Growth Factor Receptor; Vascular Endothelial Growth Factor Receptor; Medullary Thyroid Cancer; Vandetanib; Sporadic Disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Vandetanib, an orally active, small-molecule, multi-targeted tyrosine kinase inhibitor, demonstrates potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR)-2 and -3, epidermal growth factor receptor (EGFR) and the rearranged during transfection (RET) tyrosine kinase receptor.
引用
收藏
页码：1423 / 1436
页数：13
相关论文
共 101 条
[1]  
Pitt S.C.(2010)Medullary, anaplastic, and metastatic cancers of the thyroid Semin Oncol 37 567-79
[2]  
Moley J.F.(2012)Completing the arc: targeted inhibition of RET in medullary thyroid cancer J Clin Oncol 30 200-2
[3]  
Houvras Y.(2007)Medullary thyroid cancer: therapeutic targets and molecular markers Curr Opin Oncol 19 18-23
[4]  
Ball D.W.(2005)Medullary thyroid carcinoma: management of lymph node metastases Curr Treat Options Oncol 6 347-54
[5]  
Quale F.J.(2010)Medullary thyroid carcinoma: management of lymph node metastases J Natl Compr Canc Netw 8 549-56
[6]  
Moley J.F.(2008)Current management of medullary thyroid cancer Oncologist 13 539-47
[7]  
Moley J.(2010)Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis Endocr Relat Cancer 17 7-16
[8]  
Sippel R.S.(2011)Updates in the management of medullary thyroid cancer Clin Adv Hematol Oncol 9 391-4
[9]  
Kunnimalaiyaan M.(2011)Medullary thyroid cancer: an update of new guidelines and recent developments Curr Opin Oncol 23 22-7
[10]  
Chen H.(2007)New therapeutic approaches to treat medullary thyroid cancer Nat Clin Pract Endocrinol Metab 4 22-32
12345678910